FDA approves new drug developed by Coral Gables company


    The U.S. Food and Drug Administration has approved Firdapse, a new medicine developed by Coral Gables-based Catalyst Pharmaceuticals.

    The biopharmaceutical company (Nasdaq: CPRX) expects the drug to be commercially available in the first quarter of 2019. It was designed to treat Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disease that causes muscle weakness and fatigue.